'Sperm and germ'-fighting contraceptive enters trials

rm and germs, it must do so without hurting the friendly bacteria in a healthy vagina, like the lactobacilli, he explains. Also, it mustnt smell bad or taste bad or stain the sheets. And most importantly, it mustnt irritate sensitive vaginal tissues. BufferGel has met those standards both in animal trials and in extensive clinical safety trials, according to Cone.

For the new contraceptive efficacy trial, researchers at 10 sites in the United States are enrolling 1,000 women. Participants must be in a sexually active and monogamous relationship and at low risk for infection by sexually transmitted diseases. They must agree not to use other forms of contraception beyond that supplied by the study, and be willing to risk getting pregnant. Study participants will use a diaphragm with either BufferGel or a conventional spermicide.

In this trial, we want to achieve the highest possible level of protection, says Thomas Moench, medical director for ReProtect LLC. Were including a diaphragm because it places a discrete physical barrier over the cervix, significantly enhancing the protective actions of contraceptive microbicides.

Moench, formerly an assistant professor of infectious diseases at the Johns Hopkins Medical Institutions, originally created BufferGel with Cone. Hopkins and ReProtect LLC are developing BufferGel through a cooperative research agreement.

Researchers are also currently planning a larger trial to test BufferGels ability to block transmission of HIV and genital herpes. The trial is scheduled to take place through NIHs HIV Prevention Trials Network next year.


Contact: Michael Purdy
Johns Hopkins University

Page: 1 2

Related biology news :

1. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
2. UT Southwestern researchers discovery may lead to gene targets for new form of contraceptive
3. Oral contraceptives increase C-reactive protein, an infIammatory biomarker
4. The contraceptive plague
5. Newly found estrogen role in males might lead to contraceptive for men
6. New study shows oral contraceptive may be effective in treating severe form of premenstrual syndrome
7. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
8. Study suggests newer oral contraceptives may be less harmful for women smokers
9. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research
10. Images reveal how rotavirus - leading cause of diarrhea - enters cells
11. Proteomic research centers target bioterrorism agents, infectious diseases

Post Your Comments:

(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
Cached News: